{
    "clinical_study": {
        "@rank": "148043", 
        "arm_group": [
            {
                "arm_group_label": "Dose 1 JTZ-951", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, 1 dose on Day 1 before hemodialysis"
            }, 
            {
                "arm_group_label": "Dose 2 JTZ-951", 
                "arm_group_type": "Experimental", 
                "description": "Tablets, 1 dose on Day 8 after hemodialysis"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics\n      (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage\n      renal disease (ESRD) receiving hemodialysis"
        }, 
        "brief_title": "Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Anemia in Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have ESRD and have been receiving maintenance hemodialysis for at least\n             12 weeks prior to the Screening Visit\n\n          -  Body weight (post-dialysis weight) greater than 45.0 kg and a body mass index between\n             20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit\n\n        Exclusion Criteria:\n\n          -  Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to\n             admission\n\n          -  Uncontrolled hypertension at the Screening Visit or Day -1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978587", 
            "org_study_id": "AZ951-U-13-005"
        }, 
        "intervention": {
            "arm_group_label": [
                "Dose 1 JTZ-951", 
                "Dose 2 JTZ-951"
            ], 
            "intervention_name": "JTZ-951", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "End-stage Renal Disease", 
            "Hemodialysis", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "March 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-label, Sequential Crossover Study to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease", 
        "overall_official": {
            "affiliation": "Akros Pharma Inc.", 
            "last_name": "Hideyuki Yamamoto", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax (maximum concentration) of JTZ-951 when administered before and after hemodialysis", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 4 and 8 to 11"
            }, 
            {
                "measure": "tmax (time to reach maximum concentration) of JTZ-951 when administered before and after hemodialysis", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 4 and 8 to 11"
            }, 
            {
                "measure": "AUC (area under the concentration-time curve) of JTZ-951 when administered before and after hemodialysis", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 4 and 8 to 11"
            }, 
            {
                "measure": "t1/2 (elimination half-life) of JTZ-951 when administered before and after hemodialysis", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 4 and 8 to 11"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978587"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Vital signs and ECG (electrocardiogram)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }
        ], 
        "source": "Akros Pharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Akros Pharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}